Celcuity Inc. (CELC)

Celcuity Inc. is trading at $66.01, up 7.23% on the session. The 50 day average sits at $81.03 and the 200 day at $102.02, which puts the stock in a downtrend. RSI is at 33.9, which reads as weak, and MACD is bearish crossover. Volume is below average.

The nearest support is around $53.54 with resistance near $87.50, so that band frames the current range. Average daily movement is roughly $4.37, or about 6.6% of the share price, which is what any stop placement has to allow for. The overall health score of 16 out of 100 combines a trend score of 0, momentum of 20 and a risk score of 36.

Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) or HR+/HER2-, advanced or metastatic breast cancer (ABC), and patients with metastatic castration resistant prostate cancer (mCRPC). The company had a license agreement with Pfizer Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was incorporated in 2011 and is based in Minneapolis, Minnesota.